Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Life Technologies Corporation (LIFE) has launched Pervenio Lung RS, a molecular test to identify early stage lung cancer patients.
Subscribe to our email newsletter
Pervenio Lung RS is also expected to meet prognostic information needed to guide preventative treatment and improve disease management.
The test consists of a quantitative PCR (polymerase chain reaction) assay measuring expression of a proprietary 14-gene panel using formalin-fixed, paraffin-embedded tumor specimens.
The assay was developed based on technology licensed from the University of California, San Francisco by Pinpoint Genomics which Life Technologies acquired.
University of California cardiothoracic surgery associate professor and test co-developer Michael Mann said lung cancer patients who are initially diagnosed with early stage disease are dying from recurrences without having received any early post-operative intervention.
"Pervenio Lung RS has been documented to better identify the earliest stage, high-risk patients than the criteria currently suggested by these guidelines," Mann added.